Financial Performance - The company's operating revenue for the current period reached RMB 39,970,331 thousand, representing a year-on-year increase of 7.39% compared to RMB 37,220,451 thousand in the same period last year[15]. - The net profit attributable to shareholders for the current period was RMB 2,811,248 thousand, an increase of 8.54% from RMB 2,589,996 thousand in the previous year[15]. - The net profit after deducting non-recurring gains and losses was RMB 2,598,509 thousand, reflecting a 12.96% increase from RMB 2,300,375 thousand in the same period last year[16]. - Total profit reached RMB 3,532,692 thousand, reflecting a growth of 6.02% compared to the previous year[35]. - The basic earnings per share for the current period were RMB 1.729, up 8.54% from RMB 1.593 in the same period last year[16]. - The total revenue for the group reached RMB 39,832,674 thousand, representing a year-on-year increase of 7.41%[42]. - The revenue from the health segment was RMB 7,047,787 thousand, with a year-on-year growth of 8.07%[42]. Cash Flow and Assets - The net cash flow from operating activities showed a significant decline, amounting to (RMB 740,710 thousand), a decrease of 143.26% compared to RMB 1,712,214 thousand in the previous year[16]. - The total assets at the end of the current period were RMB 73,607,239 thousand, a decrease of 1.42% from RMB 74,665,299 thousand at the end of the previous year[16]. - The cash and cash equivalents as of June 30, 2023, amounted to RMB 19,787,561 thousand, a decrease from RMB 20,804,699 thousand at the end of 2022[45]. - The company's bank borrowings increased to RMB 12,142,688 thousand, up 13.78% from RMB 10,675,850 thousand at the end of 2022[46]. - The total liabilities decreased to RMB 38.23 billion as of June 30, 2023, down from RMB 41.03 billion at the end of 2022, representing a reduction of 6.8%[163]. - The total current assets amounted to approximately RMB 53.82 billion, a decrease from RMB 57.06 billion at the end of 2022, reflecting a decline of about 5.5%[158]. Investments and R&D - R&D expenses amounted to RMB 400,574 thousand, a decrease of 9.23% from the previous year[39]. - The company invested RMB 3.34 billion in the establishment of the Guoyao Fund, enhancing its capital operation capabilities[39]. - The company is in the investment expansion phase of its large medical sector, focusing on medical services, traditional Chinese medicine health management, and modern elderly care[25]. - The company has a comprehensive technology innovation system with 5 national-level R&D institutions and 17 provincial-level technology centers[33]. - The company launched new products including mountain camellia-flavored herbal tea and Wang Xiaojiji mini cans, expanding its product lineup[36]. Corporate Governance and Compliance - The financial report for the reporting period was prepared in accordance with Chinese accounting standards and is unaudited[3]. - The board of directors confirmed the authenticity, accuracy, and completeness of the financial report[3]. - The company has adhered to the corporate governance code and continuously improved its governance structure and information disclosure practices[73]. - The audit committee consists of four independent non-executive directors, ensuring compliance with accounting principles and standards, with no objections raised regarding the accounting treatment methods adopted by the company[77]. - The company is committed to enhancing its internal control and risk management systems to support high-quality development[73]. Environmental Responsibility - The company has successfully maintained compliance with environmental standards, with no exceedance in the discharge of total VOCs, COD, and other pollutants across its facilities[82]. - The company has implemented various pollution control facilities to ensure emissions are within standards, including a wastewater treatment facility with a daily processing capacity of 3,895 cubic meters per hour[84]. - The company has established a VOCs treatment system with a capacity of 12,000 cubic meters per hour, focusing on benzene and non-methane total hydrocarbons[85]. - The company has adopted clean energy for boiler combustion and is using energy-efficient equipment to reduce carbon emissions[90]. - The company has engaged third-party monitoring agencies to ensure compliance with environmental regulations[87]. Related Party Transactions - The total amount of related party transactions for the reporting period was RMB 258,917,000, with various transactions categorized under purchasing goods, providing services, and asset leasing[107]. - The company has maintained a consistent pricing principle based on market prices for its related party transactions[107]. - The non-operating fund occupation by controlling shareholders and related parties amounted to RMB 218.77 million, with a repayment of RMB 173.37 million during the reporting period[103]. - The remaining balance of non-operating fund occupation at the end of the reporting period was RMB 45.40 million, accounting for 0.13% of the latest audited net assets[103]. Market Position and Strategy - The core brand "Wanglaoji" has ranked first in the Chinese Brand Power Index for herbal tea for seven consecutive years, maintaining its leading position in the herbal tea industry[28]. - The company is leveraging digital and intelligent technologies to create new development opportunities in the pharmaceutical industry[26]. - The company has a strong marketing network with long-term partnerships with over tens of thousands of clients across more than 30 provinces, cities, and autonomous regions[32]. - The company is focused on expanding its health management and investment in the health industry[188]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[163].

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2023年半年度報告摘要 一、 重要提示 1.1 本公司半年度報告摘要摘自本公司截至2023年6月30日止六個月的2023年半年度報告全 文，投資者欲瞭解詳細內容，應當仔細閱讀將刊載於上交所網站（http://www.sse.com.cn） 等中國證監會指定網站和港交所網站（http://www.hkex.com.hk）上的半年度報告全文。 1.2 本公司董事會、監事會及其董事、監事、高級管理人員保證本摘要內容的真實、準確、完 整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律責任。 1.3 本公司董事出席了第九屆董事會第三次會議，其中，獨立非執行董事陳亞進先生因公務未 能親自出席本次董事會會議，委託獨立非執行董事黃民先生代為出席並行使表決權；執行 董事劉菊妍女士、獨立非執行董事黃龍德先生和孫寶清女士以通訊方式參加了 ...

证券代码：600332 证券简称：白云山 公告编号：2023—046 广州白云山医药集团股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次会计政策变更概述 广州白云山医药集团股份有限公司（以下简称"本公司"或"公司"）于 2023 年 8 月 18 日召开 2023 年第 6 次审核委员会会议，审议通过了《关于 2023 年半 年度财务报告中补充重要会计政策的议案》，该议案无需提交本公司董事会、 监事会和股东大会审议。本次会计政策变更，是依据财政部于 2022 年 11 月 30 日发布的《企业会计准则解释第 16 号》（财会〔2022〕31 号）（以下简称"解 释第 16 号"）对公司的会计政策进行变更。 二、具体情况及对公司的影响 （一）本次会计政策变更原因 2022 年 11 月 30 日，财政部发布了解释第 16 号，其中"关于单项交易产 生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理"的规定自 2023 年 1 月 1 日起施行。 （二）变更日期 ...

证券代码：600332 证券简称：白云山 公告编号：2023-045 广州白云山医药集团股份有限公司 第九届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届监事会第二 次会议（"会议"）于 2023 年 8 月 7 日以书面及电邮方式发出通知，会议 于 2023 年 8 月 18 日（星期五）在本公司所在地中国广东省广州市荔湾区 沙面北街 45 号公司会议室召开。本次会议应到监事 3 人，实到监事 3 人， 监事会主席蔡锐育先生主持了会议，会议的召集、召开符合《公司法》及 《公司章程》的规定。 经与会监事审议、表决，会议审议通过了如下议案： 一、本公司 2023 年半年度报告及其摘要 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 二、本公司 2023 年半年度财务报告 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 三、对本公司 2023 年半年度报告的书面审核意见 表决结果：同意票 3 票，反 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）发布的 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 以及《上海证券交易所上市公司自律监管指南第 1 号——公告格式》的 相关规定，广州白云山医药集团股份有限公司（以下简称"本公司"、 "公司"或"白云山"）就 2023 年半年度募集资金存放与实际使用情 况专项说明如下： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额及资金到账时间 证券代码：600332 证券简称：白云山 公告编号：2023－047 广州白云山医药集团股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的专项报告 根据本公司第六届董事会第八次会议及第六届董事会第十三次会议 决议，经中国证监会出具的《关于核准广州白云山医药集团股份有限公 司非公开发行股票的批复》（证监许可【2016】826 号）核准，本公司 非公开发行人民币普通股 334,711, ...

证券代码：600332 证券简称：白云山 公告编号：2023－044 广州白云山医药集团股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第三次会议 （"会议"）于 2023 年 8 月 7 日以书面及电邮方式发出通知，会议于 2023 年 8 月 18 日（星期五）在中国广东省广州市荔湾区沙面北街 45 号公司会议室召开。 本次会议应到董事 11 人，实到董事 11 人，其中，独立非执行董事陈亚进先生 因公务未能亲自出席本次董事会会议，委托独立非执行董事黄民先生代为出席 并行使表决权；执行董事刘菊妍女士、独立非执行董事黄龙德先生和孙宝清女 士以通讯方式参加了会议；董事长李楚源先生主持了会议；本公司监事、中高 级管理人员、会计师及律师列席了会议，会议的召集、召开符合《公司法》及 《公司章程》的规定。 为借助中医药领域优势继续深耕医药健康领域，同意公司与美晨集团股份 有限公司（"美晨集团"）合资设立广药白云牙膏（广州）有限公司，以 ...

广州白云山医药集团股份有限公司独立董事 关于公司 2023 年半年度募集资金存放与实际使用情况 专项报告的独立意见 广州白云山医药集团股份有限公司（"公司"）于 2023 年 8 月 18 日召开 第九届董事会第三次会议。根据《上市公司独立董事规则》《上市公司治 理准则》等法律法规的相关规定，作为公司的独立董事，经认真审阅公司 《2023 年半年度募集资金存放与实际使用情况的专项报告》，基于独立判 断的立场，我们认为公司募集资金存放与实际使用情况符合有关规定，遵 循了公平、公正、公开原则，不会损害公司及中小股东的利益。 独立董事：陈亚进、黄民、黄龙德、孙宝清 广州白云山医药集团股份有限公司 2023 年 8 月 18 日 1 ...

证券代码：600332 证券简称：白云山 公告编号：2023-043 广州白云山医药集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 25 日(星期五) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频和网络互动 （二） 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心视频和网络互动 三、 参加人员 公司参加本次说明会的人员包括：执行董事兼总经理黎洪先生、 独立非执行董事黄民先生、董事会秘书黄雪贞女士和财务副总监刘菲 女士等。 投资者可于 2023 年 8 月 18 日(星期五) 至 8 月 24 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 sec@ ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 21,628,521 thousand, representing a year-on-year increase of 5.31%[4] - The net profit attributable to shareholders was RMB 1,908,600 thousand, reflecting a growth of 5.70% compared to the same period last year[4] - Basic earnings per share for the quarter stood at RMB 1.174, marking a 5.70% increase from the previous year[5] - The net profit for Q1 2023 was approximately ¥1.97 billion, an increase from ¥1.89 billion in Q1 2022, representing a growth of about 4.6%[17] - The operating profit for Q1 2023 was ¥2.35 billion, compared to ¥2.26 billion in Q1 2022, showing an increase of approximately 4%[17] - The total comprehensive income for Q1 2023 was approximately ¥1.96 billion, compared to ¥1.89 billion in Q1 2022, representing an increase of about 3.7%[18] Cash Flow - The net cash flow from operating activities was negative at RMB (2,838,882) thousand, a significant decrease of 409.22% year-on-year[4][7] - The cash flow from operating activities showed a net outflow of approximately ¥2.84 billion, contrasting with a net inflow of ¥918.06 million in Q1 2022[20] - Net cash flow from investment activities was (¥638,055,604.71), worsening from (¥429,198,901.93) year-over-year[21] - Net cash flow from financing activities improved to ¥1,571,436,553.79, compared to ¥848,637,912.69 in the previous year, showing an increase of about 85%[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 73,658,300 thousand, down 1.35% from the end of the previous year[5] - Current assets totaled ¥55,437,164,388.07 as of March 31, 2023, a decrease of 2.2% from ¥57,064,311,513.29 at the end of 2022[12] - Non-current assets increased to ¥18,221,135,787.49 from ¥17,600,987,263.45, marking a growth of 3.5%[13] - Total liabilities decreased to ¥38,057,349,122.22 from ¥41,027,440,697.52, a reduction of 7.2%[14] Shareholder Information - The equity attributable to shareholders increased to RMB 33,967,845 thousand, a rise of 5.93% compared to the previous year[5] - The total number of ordinary shareholders at the end of the reporting period was 86,846[8] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., holds 45.04% of the shares, totaling 732,305,103 shares[8] Expenses and Investments - Total operating costs for Q1 2023 were ¥19,332,774,093.08, up from ¥18,312,100,904.61 in Q1 2022, reflecting a year-over-year increase of 5.6%[15] - Research and development expenses decreased to ¥179.39 million from ¥238.88 million, reflecting a reduction of about 25%[17] - The company reported a tax expense of approximately ¥385.93 million, up from ¥372.24 million in the previous year, indicating an increase of about 3.5%[17] - The investment income for Q1 2023 was approximately ¥81.73 million, a substantial increase from ¥20.90 million in the same period last year, reflecting a growth of about 290%[17] Cash and Equivalents - The company's cash and cash equivalents were ¥20,245,924,699.78, down 10.0% from ¥22,499,552,770.75 in the previous year[12] - The ending balance of cash and cash equivalents stood at ¥18,900,995,214.13, down from ¥22,350,305,251.23 year-over-year[21] - The net increase in cash and cash equivalents was (¥1,903,703,798.51), a decline from an increase of ¥1,336,941,209.01 in the prior year[21] Other Financial Metrics - Non-recurring gains and losses totaled RMB 81,164 thousand for the quarter, with government subsidies contributing RMB 36,754 thousand[6] - The weighted average return on equity decreased by 0.25 percentage points to 5.78%[5] - Long-term borrowings increased significantly to ¥3,136,584,449.64 from ¥1,639,203,064.38, indicating a rise of 91.2%[14] - Total cash inflow from investment activities reached ¥284,035,293.15, compared to ¥74,603,372.98 in the previous year, marking an increase of approximately 280%[21] - Cash outflow from investment activities totaled ¥922,090,897.86, up from ¥503,802,274.91, representing an increase of about 83%[21] - Cash inflow from financing activities amounted to ¥6,768,424,606.31, compared to ¥4,745,085,207.77, reflecting a growth of around 42.6%[21] - Cash outflow from financing activities was ¥5,196,988,052.52, an increase from ¥3,896,447,295.08, indicating a rise of approximately 33.4%[21] Accounting Standards - The company did not implement new accounting standards or interpretations for the current fiscal year[21]

香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本報告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2023年第一季度報告 重要內容提示 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）、監事會及董事、監事、高級管理人 員保證季度報告內容的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別 和連帶的法律責任。 本公司董事長李楚源先生、財務副總監劉菲女士及財務部副部長吳楚玲女士保證季度報告中財務信 息的真實、準確、完整。 第一季度財務報表是否經審計 □是 ✔否 季度報告分別以中、英文兩種語言編訂，兩種文本若出現解釋上的歧義時，以中文本為準。 ...